Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMI:TSE International Medical Innovations Inc. -- Ignore unavailable to you. Want to Upgrade?

To: gg cox who wrote (13)	10/30/2002 6:28:42 PM
From: gg cox	Read Replies (1) \| Respond to of 66

Good reason for optimism. Posted by HarryKane on stockhouse. I know how tough it's been for eveyone seeing the price deterioration. It has happened before to vaying degrees. However there is good reason to be optimistic. Bear in mind that we've had one great run up in prices each + every year for the last 4 years. Each time it was darkest just before the dawn followed by explosive growth: Nov 1999 to March 2000, 366% in less than 5 months June to October 2000, 230% in less than 4 months Feb to June 2001 200% in less than 5 months Dec to June 2002 230% in less than 7 months stockcharts.com[h,a]dahlyiay[df][pc20!b60!f][vc60][iut!Uk14!Uh14,3]&pref=G That's an average gain of 256% per run up. I believe we are getting ready for another spike. From the $2.27 low a 256% increase means $5.81. Not bad but we could and should go much higher on subsequent runs. The Inverness model is our stated target and role model: 1000% growth in one calendar year. J+J was mainly responsible for that accomplishment and subsequently bought Inverness's main product. I know 1000% seems like a stretch in this market but we do have some very nice products about to come into play. Also we are working to a well conceived business plan with clearly stated goals and methods. Management has integrity and has executed each + every milestone they establish. From $2.27 1000% growth equals $22.70 per share or a market cap of $476.7M CDN. Sounds impossible in this market doesn't it? However we do have the products to potentially enable those targets. Earnings of $2.20 would likely justify that price, or the sale of any one major product line. Despite the bear market miracles do happen to a select few companies of which we may, hopefully, be one. Completed Milestones by timeline: CH123: Pivotal trials commence November 1997 ColorectAlert: IMI licences test for detection of early stage colorectal cancer May 1998 ColorectAlert: IMI files patent application for colorectal cancer detection test January 1999 LungAlert: IMI files patent application for lung cancer detection test January 1999 ColorectAlert: Announced May 2000, clinically more accurate than fecal occult blood testing (FOBT) CH123: January 29, 2001, Canadian marketing clearance LungAlert: May 2001 American Thoracic Society, 1st and only early stage test CH123: June 11, 2001 FDA submission CH123: July 10, 2001 DCL agrees to make CH123 CH123: September 5, 2001 SG Cowen Securities hired CH123: October 29, 2001 resubmission to FDA, shares tank to $3.00 CH123: February 25, 2002 Multi-Ethnic Study of Atherosclerosis (MESA 6500 souls) CH123: April 8, 2002 Sprecher breakthrough at American Heart Association ColorectAlert: April 15, 2002 ColorectAlert beats FOBT financially CH123: May 10, 2002 McNeil CDN partnership announced CH123: June 2002 American Journal of Cardiology paper, Mancini CH123: June 24, 2002 FDA approval CH123: Sept. 2002 European approval CH123 @ home: Unveiling of new modified home tests Oct Q4 2002 CH123: Oct. 28th, McNeil demos 123 at the Canadian Cardiovascular Congress, Edmonton Milestones yet to come with approx. timing: US stock listing Q4 2002 CH123: Revenue stream commences Q4 2002 CH123: Japanese Approval Process, completing Q4 2002 CH123: Announcement of World Wide and or US Partners Q4 2002 CH123 @ home: Clinical trials (100 souls) commence Oct Q4 2002 CH123 @ home: Clinical trials (100 souls) completed Dec Q4 2002 CH123 @ home: CDN approval + FDA 510K submission Q1 2003 substantially equivalent to CH123? CH123 @ home: FDA approval Q3 2003 ColorectAlert: Trials completed Q4 2002 (2000 souls) ColorectAlert: Papers submitted Q1 2002 ColorectAlert: Canadian Approval Q2 2003 ColorectAlert: FDA submission Q3 2003 ColorectAlert: FDA approval mid 2004 ColorectAlert: Marketing Partner late 2004 LungAlert: Interim Papers to be submitted this fall Q4 2002 LungAlert: Completion of trials Q1 2003 LungAlert: Canadian Approval Q3 2003 LungAlert: FDA submission Q1 2004 LungAlert: FDA approval late 2004 LungAlert: Marketing Partner late 2004 BreastAlert: Nipple Aspirate testing commences Q2 2002 BreastAlert: Market in 2005/6 stockhouse.com